[PDF][PDF] Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia
J Clin Oncol, 2012•researchgate.net
Purpose There has been little survival improvement in older patients with acute myeloid
leukemia (AML) in the last two decades. Improving induction treatment may improve the rate
and quality of remission and consequently survival. In our previous trial, in younger patients,
we showed improved survival for the majority of patients when adding gemtuzumab
ozogamicin (GO) to induction chemotherapy.
leukemia (AML) in the last two decades. Improving induction treatment may improve the rate
and quality of remission and consequently survival. In our previous trial, in younger patients,
we showed improved survival for the majority of patients when adding gemtuzumab
ozogamicin (GO) to induction chemotherapy.
Purpose
There has been little survival improvement in older patients with acute myeloid leukemia (AML) in the last two decades. Improving induction treatment may improve the rate and quality of remission and consequently survival. In our previous trial, in younger patients, we showed improved survival for the majority of patients when adding gemtuzumab ozogamicin (GO) to induction chemotherapy.
researchgate.net